UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2022
Shockwave Medical, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38829 | 27-0494101 | ||||||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
5403 Betsy Ross Drive
Santa Clara, California 95054
(Address of Principal Executive Offices) (Zip Code)
(510) 279-4262
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common stock, par value $0.001 per share | SWAV | The Nasdaq Stock Market LLC | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders
Shockwave Medical, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 23, 2022 (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended. At the close of business on April 25, 2022, the record date for the Annual Meeting, there were 35,785,441 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote, and 31,963,071 of such shares were voted in person or by proxy at the Annual Meeting on the proposals described below.
At the Annual Meeting, the Company’s stockholders voted on the following three proposals, each of which is described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2022. The number of votes cast with respect to each proposal was as indicated below:
1.Election of Directors. The following nominees were elected to serve as Class III directors until the Company’s 2025 annual meeting of stockholders and until their respective successors are duly elected and qualified, or, if sooner, until the director’s death, resignation or removal, based on the following results of voting:
| Nominee | Votes For | Vote Withheld | Broker Non-Votes | |||||||||||||||||
| Doug Godshall | 21,799,472 | 6,916,988 | 3,246,611 | |||||||||||||||||
| F.T. “Jay” Watkins | 21,688,938 | 7,027,522 | 3,246,611 | |||||||||||||||||
| Frederic Moll, M.D. | 19,387,707 | 9,328,753 | 3,246,611 | |||||||||||||||||
2.Ratification of the Selection of the Independent Registered Public Accounting Firm. The selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2022 was ratified based on the following results of voting:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 31,819,908 | 123,840 | 19,323 | N/A | |||||||||||||||||
3.Advisory Vote on the Compensation of the Company's Names Executive Officers. The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following results of voting:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 27,185,083 | 1,504,980 | 26,397 | 3,246,611 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Shockwave Medical, Inc. | ||||||||
| Date: June 24, 2022 | By: | /s/ Daniel K. Puckett | ||||||
| Daniel K. Puckett | ||||||||
| Chief Financial Officer | ||||||||